Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase EARLY_PHASE1 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3CNS 2

Conditions

Multiple Myeloma 1086Neoplasms, Plasma Cell 255Lymphoma 157Lymphoma, Non-Hodgkin 150Hodgkin Disease 135Recurrence 130Leukemia, Lymphocytic, Chronic, B-Cell 130Precursor Cell Lymphoblastic Leukemia-Lymphoma 116Myelodysplastic Syndromes 111Leukemia 109Leukemia, Myeloid, Acute 106Lymphoma, Follicular 84Lymphoma, Mantle-Cell 83Lymphoma, B-Cell, Marginal Zone 82Burkitt Lymphoma 76Lymphoma, Large B-Cell, Diffuse 74Myeloproliferative Disorders 70Immunoglobulin Light-chain Amyloidosis 67Lymphoma, Large-Cell, Immunoblastic 65Hematologic Neoplasms 63Primary Myelofibrosis 58Leukemia, Myeloid, Chronic-Phase 57Leukemia, Myeloid, Accelerated Phase 51Leukemia, Myelogenous, Chronic, BCR-ABL Positive 49Waldenstrom Macroglobulinemia 46Blast Crisis 44Congenital Abnormalities 43Leukemia, Myelomonocytic, Chronic 42Dendritic Cell Sarcoma, Interdigitating 42Smoldering Multiple Myeloma 41

Interventions

Dexamethasone 2pomalidomide 1birtamimab 1Melphalan 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Alzheimer Disease × Plasma cell × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed
129 enrolled 18 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡